Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 140.86M | 134.37M | 126.42M | 139.42M | 152.92M |
| Total Other Revenue | 2.37M | 1.21M | 11.10K | 11.10K | 11.10K |
| Total Revenue | 143.23M | 135.58M | 126.43M | 139.43M | 152.93M |
| Cost of Revenue | 21.74M | 21.72M | 21.58M | 19.61M | 17.74M |
| Gross Profit | 121.49M | 113.86M | 104.84M | 119.82M | 135.19M |
| SG&A Expenses | 3.10M | 3.29M | 3.46M | 3.69M | 3.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.84M | 25.01M | 25.04M | 23.30M | 21.69M |
| Operating Income | 118.39M | 110.57M | 101.38M | 116.13M | 131.24M |
| Income Before Tax | 120.86M | 115.79M | 109.39M | 122.06M | 135.13M |
| Income Tax Expenses | 27.02M | 30.01M | 32.73M | 32.07M | 31.44M |
| Earnings from Continuing Operations | 93.85 | 85.79 | 76.66 | 89.99 | 103.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.85M | 85.79M | 76.66M | 89.99M | 103.69M |
| EBIT | 118.39M | 110.57M | 101.38M | 116.13M | 131.24M |
| EBITDA | 118.40M | 110.59M | 101.40M | 116.14M | 131.25M |
| EPS Basic | 0.73 | 0.67 | 0.60 | 0.71 | 0.81 |
| Normalized Basic EPS | 0.59 | 0.57 | 0.54 | 0.60 | 0.66 |
| EPS Diluted | 0.72 | 0.65 | 0.58 | 0.69 | 0.79 |
| Normalized Diluted EPS | 0.58 | 0.55 | 0.52 | 0.58 | 0.64 |
| Average Basic Shares Outstanding | 511.08M | 511.01M | 510.95M | 509.62M | 508.28M |
| Average Diluted Shares Outstanding | 523.12M | 523.87M | 524.61M | 523.84M | 523.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |